14-day Premium Trial Subscription Sign Up For FreeGet Free

Weaker Stock
Today ESPR ranks #16510 as sell candidate. Get a Free Stock at Robinhood
Stronger Stock

Esperion Therapeutics Stock Forecast NASDAQ:ESPR

$5.87 (5.58%)

Volume: 3M

Closed: Dec 08, 2021

Hollow Logo Score: -6.572

Esperion Therapeutics Stock Forecast

$5.87 (5.58%)

Volume: 3M

Closed: Dec 08, 2021

Score Hollow Logo -6.572

Esperion Therapeutics Stock Forecast NASDAQ:ESPR

Price Target and Analyst Ratings

Most Recent Rating

On Dec 06, 2021 "Credit Suisse Group" gave "$11.00 - $8.00" rating for ESPR. The price target was set to $5.26+0.2%.

Last 30 Days

Historical Ratings

Date Rating Action Authority Current Price Target Price
2021-12-06 $11.00 - $8.00 Target Lowered by Credit Suisse Group $5.61 $5.26+0.2%
2021-10-19 $60.00 - $30.00 Target Lowered by Cowen $9.55 $8.98+1.4%
2021-10-18 Downgraded by Credit Suisse Group $8.86 $8.86→3.1%
2021-10-14 $11.00 Downgraded by Morgan Stanley $9.30 $10.40+1.0%
2021-09-22 $16.00 - $8.00 Target Lowered by The Goldman Sachs Group $11.88 $12.92+3.7%
2021-09-14 $90.00 Reiterated by JMP Securities $11.59 $11.38→3.6%
2021-08-04 $22.00 - $17.00 Target Lowered by Morgan Stanley $14.00 $14.27→4.8%
2021-08-03 $134.00 - $114.00 Target Lowered by Needham & Company LLC $14.27 $14.38→4.1%
2021-05-11 Outperform Target Lowered by Credit Suisse Group $21.97 $45.00 → $36.00
2021-05-11 Buy - Hold Reiterated by Stifel Nicolaus $21.97 $37.00 → $20.00
2021-05-11 Equal Weight Target Lowered by Morgan Stanley $21.97 $30.00 → $22.00
2021-05-11 Market Outperform Target Lowered by JMP Securities $21.97 $191.00 → $111.00
2021-05-11 Market Perform Target Lowered by Northland Securities $21.97 $30.00 → $24.00
2021-05-05 Buy - Hold Downgraded by Stifel Nicolaus $20.01 $37.00 → $20.00
2021-05-05 Equal Weight Target Lowered by Morgan Stanley $20.01 $30.00 → $22.00
2021-05-05 Outperform Target Lowered by JMP Securities $20.01 $191.00 → $111.00
2021-05-05 Outperform Target Lowered by Credit Suisse Group $20.01 $45.00 → $36.00
2021-05-05 Market Perform Target Lowered by Northland Securities $20.01 $30.00 → $24.00
2021-05-05 Target Lowered by BTIG Research $20.01 $90.00 → $71.00
2021-03-17 Equal Weight Initiated by Morgan Stanley $30.10 $30.00
2021-03-11 Equal Weight Initiated by Morgan Stanley $29.39 $30.00
2021-03-03 Strong-Buy Target Lowered by Needham & Company LLC $27.49 $150.00 → $134.00
2021-02-25 Strong-Buy Target Lowered by Needham & Company LLC $27.68 $150.00 → $134.00
2021-02-12 Buy - Hold Downgraded by Jefferies Financial Group $29.86 $30.00
2021-02-09 Neutral - Sell Downgraded by The Goldman Sachs Group $33.37 $44.00 → $24.00
2021-01-15 Buy - Neutral Downgraded by Bank of America $25.55 $52.00 → $35.00
2020-11-10 Neutral - Outperform Upgraded by Credit Suisse Group $28.90 $45.00
2020-10-15 Buy Target Lowered by Bank of America $34.72 $55.00 → $52.00
2020-09-29 Underweight Initiated by JPMorgan Chase & Co. $37.46
2020-08-17 Buy Target Lowered by Bank of America $33.38 $60.00 → $55.00
2020-08-11 Buy Reiterated by Needham & Company LLC $33.48 $158.00
2020-08-10 Outperform - Neutral Downgraded by Credit Suisse Group $37.00 $83.00 → $45.00
2020-08-10 Buy Reiterated by Stifel Nicolaus $37.00 $75.00
2020-06-29 Buy Initiated by Credit Suisse Group $47.64 $83.00
2020-06-26 Buy Reiterated by Stifel Nicolaus $45.90 $75.00
2020-06-23 Hold Initiated by Northland Securities $47.42 $42.00
2020-05-07 Buy Reiterated by Needham & Company LLC $44.12
2020-05-07 Hold Reiterated by Northland Securities $44.12 $42.00
2020-05-07 Buy Target Raised by Citigroup $44.12 $46.00 → $56.00
2020-05-07 Buy Target Lowered by Jefferies Financial Group $44.12 $85.00 → $70.00
2020-04-16 Market Perform Target Lowered by Northland Securities $35.86 $60.00 → $42.00

ESPR Stock Trend

The stock lies in the middle of a very wide and falling trend in the short term and further fall within the trend is signaled.

Given the current short-term trend, the stock is expected to fall -37.25% during the next 3 months and, with a 90% probability hold a price between $3.13 and $5.75 at the end of this 3-month period. Do note, that if the stock price manages to stay at current levels or higher, our prediction target will start to change positively over the next few days as the conditions for the current predictions will be broken.

Data

Date Bottom Mid Top
2021-12-10 $4.90 $6.99 $9.07
2021-12-13 $4.82 $6.90 $8.98
2021-12-14 $4.73 $6.82 $8.90
2021-12-15 $4.65 $6.73 $8.81
2021-12-16 $4.56 $6.64 $8.73
2021-12-17 $4.47 $6.56 $8.64
2021-12-20 $4.39 $6.47 $8.55
2021-12-21 $4.30 $6.38 $8.47
2021-12-22 $4.21 $6.30 $8.38
2021-12-23 $4.13 $6.21 $8.29
2021-12-27 $4.04 $6.12 $8.21
2021-12-28 $3.96 $6.04 $8.12
2021-12-29 $3.87 $5.95 $8.04
2021-12-30 $3.78 $5.87 $7.95
2021-12-31 $3.70 $5.78 $7.86
2022-01-03 $3.61 $5.69 $7.78
2022-01-04 $3.52 $5.61 $7.69
2022-01-05 $3.44 $5.52 $7.60
2022-01-06 $3.35 $5.43 $7.52
2022-01-07 $3.27 $5.35 $7.43
2022-01-10 $3.18 $5.26 $7.34
2022-01-11 $3.09 $5.18 $7.26
2022-01-12 $3.01 $5.09 $7.17
2022-01-13 $2.92 $5.00 $7.09
2022-01-14 $2.83 $4.92 $7.00
2022-01-17 $2.75 $4.83 $6.91
2022-01-18 $2.66 $4.74 $6.83
2022-01-19 $2.57 $4.66 $6.74
2022-01-20 $2.49 $4.57 $6.65
2022-01-21 $2.40 $4.49 $6.57

About Esperion Therapeutics

Esperion Therapeutics, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of oral and low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of patients with elevated LDL-C. Its lead product candidate is ETC-1002 or Bempedoic acid, an inhibitor of ATP Citrate Lyase, an enzyme on the cholesterol biosynthesis pathway that is in Phase III long-term safety and tolerability study to... Read more

Golden Star Signal

This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.

This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!

Get access to Golden Star list now!

StockInvest.usJoin 100 000+ Happy Subscribers

Don't miss out on the runners!

Get The StockInvest.Us Newsletter

StockInvest.usStock Podcast

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT